2,3-dipalmitoyl-S-glycerylcysteine | 656831-18-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,3-dipalmitoyl-S-glycerylcysteine
• 英文别名: (2R)-2-amino-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]propanoic acid
• CAS: 656831-18-4
• 化学式: C₃₈H₇₃NO₆S
• 分子量: 672.1
• InChiKey: UPAQRWMRKQCLSD-HTIIIDOHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.8
• 重原子数：
  46
• 可旋转键数：
  38
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  141
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS
  申请人：CAYLA

  公开号：US20140141033A1

  公开（公告）日：2014-05-22

  A conjugated compound of formula Q-Z—R 4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R 4 is a TLR2 agonist, and the uses thereof in the treatment of infection, cancer or immune disorders or for use in vaccines.

  一种配方为Q-Z—R4的共轭化合物，其中Q是TLR7和/或TLR8激动剂，Z—R4是TLR2激动剂，以及它们在治疗感染、癌症或免疫紊乱或用于疫苗中的用途。
• [EN] CANCER IMMUNOTHERAPY<br/>[FR] IMMUNOTHÉRAPIE ANTICANCÉREUSE
  申请人：ENA THERAPEUTICS PTY LTD

  公开号：WO2021042171A1

  公开（公告）日：2021-03-11

  Methods, compounds, compositions and kits for the treatment and/or prevention of cancer are provided. In particular, methods for the treatment of cancer comprising the administration of a TLR2 agonist, such as a conjugate of dipalmitoyl-S-glyceryl-cysteine (Pam2Cys) and polyethylene glycol (PEG), more particularly a Pam2Cys-Ser-PEG compound, and an immunostimulant such as an anti-PD-1, anti-PDL-1, anti-PL- 1, or anti-CTLA-4 immunotherapeutic, are provided.

  提供了治疗和/或预防癌症的方法、化合物、组合物和工具包。特别地，提供了治疗癌症的方法，包括给予TLR2激动剂，例如二棕榈酰-S-甘油半胱氨酸（Pam2Cys）和聚乙二醇（PEG）的共轭物，更具体地说是Pam2Cys-Ser-PEG化合物，以及免疫刺激剂，例如抗PD-1、抗PDL-1、抗PL-1或抗CTLA-4免疫治疗剂。
• SYNTHETIC IMMUNOGEN USEFUL FOR GENERATING LONG LASTING IMMUNITY AND PROTECTION AGAINST PATHOGENS
  申请人：Agrewala Javed Naim

  公开号：US20130183377A1

  公开（公告）日：2013-07-18

  The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, AIDS, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent HLA restriction in humans and livestock. The invention further relates to a vaccine comprising the said immunogen for generating enduring protective immunity against various diseases. The said vaccine is targeted against intracellular pathogens, more particularly the pathogen M. tuberculosis in this case. In the present invention, promiscuous peptides of M. tuberculosis are conjugated to TLR ligands especially; Pam2Cys to target them mainly to dendritic cells and therefore elicit long-lasting protective immunity. (The formula (I) should be inserted here) General formula (I) wherein, X 1 =a promiscuous CD4 T helper epitope selected from SEQ ID No. 1 to 98 OR nil; X 2 =a promiscuous CD8 T cytotoxic epitope selected from SEQ ID No. 99 to 103 OR nil; when X1=nil; X2=SEQ ID No. 99 to 103 and when X2=nil; X1=SEQ ID No. 1 to 98; Y=Lysine; and S=Serine.

  本发明涉及一种由通式1表示的合成免疫原，可用于产生长期的保护性免疫力，以对抗导致结核病、利什曼病、艾滋病、锥虫病、疟疾、过敏和癌症等各种细胞内病原体。所开发的免疫原能够规避人类和家畜的HLA限制。本发明还涉及一种包括所述免疫原的疫苗，用于产生长期的保护性免疫力以对抗各种疾病。该疫苗针对细胞内病原体，特别是在本例中的M. tuberculosis病原体。在本发明中，M. tuberculosis的杂交肽与TLR配体（尤其是Pam2Cys）结合，主要靶向树突状细胞，从而引发长期的保护性免疫力。（公式（I）应在此处插入）通式（I）其中，X1 = SEQ ID No. 1至98或nil中选择的杂交CD4 T辅助表位；X2 = SEQ ID No. 99至103或nil中选择的杂交CD8 T细胞毒性表位；当X1 = nil时，X2 = SEQ ID No. 99至103，当X2 = nil时，X1 = SEQ ID No. 1至98；Y = 赖氨酸；S = 丝氨酸。
• Adjuvanting Material
  申请人：Jackson David C.

  公开号：US20080233143A1

  公开（公告）日：2008-09-25

  The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group.

  本发明提供了一种辅助材料，该辅助材料包括一个脂质树突状细胞靶向基团，其中与之共价结合的是一个金属螯合基团。此外，本发明还提供了一种免疫原组合物，包括（a）一个脂质树突状细胞靶向基团，其中与之共价结合的是一个金属螯合基团；（b）一个包含金属亲和标签的抗原；以及可选的（c）金属离子，因此抗原通过金属亲和标签和金属螯合基团之间的相互作用与脂质树突状细胞靶向基团连接。
• Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes
  申请人：Jackson David

  公开号：US20070160631A1

  公开（公告）日：2007-07-12

  The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the CTL epitope.

  本发明提供了合成免疫原性脂肽分子，包括共线T细胞辅助和CTL表位，以及它们的制备和用于产生初级和次级免疫反应的方法，并用于对动物主体进行特定CTL表位的疫苗接种。更具体地，本发明提供了高度可溶的脂肽，其中脂质基团附加到内部赖氨酸或赖氨酸类似物的末端侧链基团上，优选地附加到内部二氨基酸残基的末端侧链基团上。最好的情况是，在T细胞辅助表位和CTL表位之间放置内部赖氨酸或赖氨酸类似物。